AbbVie Inc. Net Income (Loss) Available to Common Stockholders, Basic
AbbVie Inc. (ABBV) reported Net Income (Loss) Available to Common Stockholders, Basic of $3.60 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-03
- AbbVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $3.60B, a 288.04% increase year-over-year.
- AbbVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $685.00M, a 46.32% decline year-over-year.
- AbbVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $1.81B.
- AbbVie Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $176.00M, a 88.65% decline year-over-year.
- AbbVie Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $4.19B, a 1.23% decline from fiscal 2024.
- AbbVie Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was $4.24B, a 12.07% decline from fiscal 2023.
- AbbVie Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was $4.82B, a 59.09% decline from fiscal 2022.
- AbbVie Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $11.78B, a 2.74% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.60B 10-Q · filed 2026-08-03 | $4.29B 10-Q · filed 2026-08-03 | $6.09B derived: sum of 3 quarters · filed 2026-08-03 | $6.27B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $685.00M 10-Q · filed 2026-05-08 | $2.49B derived: sum of 2 quarters · filed 2026-05-08 | $2.67B derived: sum of 3 quarters · filed 2026-05-08 | $3.60B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $1.81B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.98B derived: sum of 2 quarters · filed 2026-02-20 | $2.91B derived: sum of 3 quarters · filed 2026-08-03 | $4.19B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $176.00M 10-Q · filed 2025-11-04 | $1.10B derived: sum of 2 quarters · filed 2026-08-03 | $2.38B 10-Q · filed 2025-11-04 | $2.35B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $928.00M 10-Q · filed 2026-08-03 | $2.20B 10-Q · filed 2026-08-03 | $2.17B derived: sum of 3 quarters · filed 2026-08-03 | $3.72B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | $1.28B 10-Q · filed 2026-05-08 | $1.24B derived: sum of 2 quarters · filed 2026-05-08 | $2.79B derived: sum of 3 quarters · filed 2026-05-08 | $4.16B derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | -$32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.52B derived: sum of 2 quarters · filed 2026-02-20 | $2.88B derived: sum of 3 quarters · filed 2026-02-20 | $4.24B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $1.55B 10-Q · filed 2025-11-04 | $2.91B derived: sum of 2 quarters · filed 2025-11-04 | $4.27B 10-Q · filed 2025-11-04 | $5.08B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $1.36B 10-Q · filed 2025-08-04 | $2.72B 10-Q · filed 2025-08-04 | $3.53B derived: sum of 3 quarters · filed 2026-02-20 | $5.30B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $1.36B 10-Q · filed 2025-05-09 | $2.17B derived: sum of 2 quarters · filed 2026-02-20 | $3.94B derived: sum of 3 quarters · filed 2026-02-20 | $5.95B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $811.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.58B derived: sum of 2 quarters · filed 2026-02-20 | $4.59B derived: sum of 3 quarters · filed 2026-02-20 | $4.82B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $1.77B 10-Q · filed 2024-11-04 | $3.78B derived: sum of 2 quarters · filed 2024-11-04 | $4.01B 10-Q · filed 2024-11-04 | $6.47B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | $2.01B 10-Q · filed 2024-08-07 | $2.24B 10-Q · filed 2024-08-07 | $4.70B derived: sum of 3 quarters · filed 2025-02-14 | $8.63B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-03-31 | $228.00M 10-Q · filed 2024-05-03 | $2.69B derived: sum of 2 quarters · filed 2025-02-14 | $6.62B derived: sum of 3 quarters · filed 2025-02-14 | $7.53B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2022-12-31 | $2.46B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $6.39B derived: sum of 2 quarters · filed 2025-02-14 | $7.31B derived: sum of 3 quarters · filed 2025-02-14 | $11.78B 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $3.93B 10-Q · filed 2023-11-06 | $4.84B derived: sum of 2 quarters · filed 2023-11-06 | $9.32B 10-Q · filed 2023-11-06 | $13.34B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $913.00M 10-Q · filed 2023-08-07 | $5.39B 10-Q · filed 2023-08-07 | $9.40B derived: sum of 3 quarters · filed 2024-02-20 | $12.56B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $4.47B 10-Q · filed 2023-05-05 | $8.49B derived: sum of 2 quarters · filed 2024-02-20 | $11.65B derived: sum of 3 quarters · filed 2024-02-20 | $12.40B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $4.02B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $7.18B derived: sum of 2 quarters · filed 2024-02-20 | $7.93B derived: sum of 3 quarters · filed 2024-02-20 | $11.47B 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | $3.16B 10-Q · filed 2022-11-04 | $3.91B derived: sum of 2 quarters · filed 2022-11-04 | $7.45B 10-Q · filed 2022-11-04 | $7.46B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $749.00M 10-Q · filed 2022-08-04 | $4.29B 10-Q · filed 2022-08-04 | $4.30B derived: sum of 3 quarters · filed 2023-02-17 | $6.59B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $3.53B 10-Q · filed 2022-05-06 | $3.55B derived: sum of 2 quarters · filed 2023-02-17 | $5.84B derived: sum of 3 quarters · filed 2023-02-17 | $5.08B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $2.31B derived: sum of 2 quarters · filed 2023-02-17 | $1.55B derived: sum of 3 quarters · filed 2023-02-17 | $4.56B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $2.29B 10-Q · filed 2021-11-02 | $1.53B derived: sum of 2 quarters · filed 2021-11-02 | $4.54B 10-Q · filed 2021-11-02 | $7.32B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | -$756.00M 10-Q · filed 2021-08-02 | $2.24B 10-Q · filed 2021-08-02 | $5.03B derived: sum of 3 quarters · filed 2022-02-18 | $6.90B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $3.00B 10-Q · filed 2021-05-07 | $5.78B derived: sum of 2 quarters · filed 2022-02-18 | $7.66B derived: sum of 3 quarters · filed 2022-02-18 | $8.39B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $2.79B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $4.66B derived: sum of 2 quarters · filed 2022-02-18 | $5.39B derived: sum of 3 quarters · filed 2022-02-18 | $7.84B 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $1.87B 10-Q · filed 2020-11-04 | $2.61B derived: sum of 2 quarters · filed 2020-11-04 | $5.05B 10-Q · filed 2020-11-04 | $3.23B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | $733.00M 10-Q · filed 2020-08-04 | $3.18B 10-Q · filed 2020-08-04 | $1.35B derived: sum of 3 quarters · filed 2021-02-19 | $4.09B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | $2.44B 10-Q · filed 2020-05-08 | $622.00M derived: sum of 2 quarters · filed 2021-02-19 | $3.36B derived: sum of 3 quarters · filed 2021-02-19 | $5.33B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | -$1.82B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $913.00M derived: sum of 2 quarters · filed 2021-02-19 | $2.89B derived: sum of 3 quarters · filed 2021-02-19 | $5.66B 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $2.73B 10-Q · filed 2019-11-06 | $4.71B derived: sum of 2 quarters · filed 2019-11-06 | $7.48B 10-Q · filed 2019-11-06 | $7.53B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | $1.97B 10-Q · filed 2019-08-05 | $4.74B 10-Q · filed 2019-08-05 | $4.80B derived: sum of 3 quarters · filed 2020-02-21 | $6.42B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $2.77B 10-Q · filed 2019-05-03 | $2.82B derived: sum of 2 quarters · filed 2020-02-21 | $4.45B derived: sum of 3 quarters · filed 2020-02-21 | $6.35B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | $52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.68B derived: sum of 2 quarters · filed 2020-02-21 | $3.58B derived: sum of 3 quarters · filed 2020-02-21 | $5.28B 10-K · filed 2020-02-21 | ||||
| 2017-09-30 | $1.62B 10-Q · filed 2018-11-07 | $3.53B derived: sum of 2 quarters · filed 2018-11-07 | $5.23B 10-Q · filed 2018-11-07 | $6.62B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $1.91B 10-Q · filed 2018-08-07 | $3.61B 10-Q · filed 2018-08-07 | $4.99B derived: sum of 3 quarters · filed 2019-02-27 | $6.58B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $1.70B 10-Q · filed 2018-05-04 | $3.09B derived: sum of 2 quarters · filed 2019-02-27 | $4.68B derived: sum of 3 quarters · filed 2019-02-27 | $6.28B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $1.38B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.97B derived: sum of 2 quarters · filed 2019-02-27 | $4.58B derived: sum of 3 quarters · filed 2019-02-27 | $5.92B 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $1.59B 10-Q · filed 2017-11-07 | $3.19B derived: sum of 2 quarters · filed 2017-11-07 | $4.54B 10-Q · filed 2017-11-07 | $6.06B derived: sum of 4 quarters · filed 2017-11-07 | ||||
| 2016-06-30 | $1.60B 10-Q · filed 2017-08-07 | $1.61B 10-Q · filed 2016-08-05 | $2.95B 10-Q · filed 2017-08-07 | $2.96B 10-Q · filed 2016-08-05 | $4.47B derived: sum of 3 quarters · filed 2017-08-07 | $5.70B derived: sum of 4 quarters · filed 2017-08-07 | ||
| 2016-03-31 | $1.35B 10-Q · filed 2017-05-05 | $1.35B 10-Q · filed 2016-05-06 | $2.86B derived: sum of 2 quarters · filed 2017-05-05 | $4.10B derived: sum of 3 quarters · filed 2017-05-05 | $5.46B derived: sum of 4 quarters · filed 2017-05-05 | |||
| 2015-12-31 | $1.52B 10-K · filed 2016-02-19 | $2.75B derived: sum of 2 quarters · filed 2016-11-07 | $4.12B derived: sum of 3 quarters · filed 2016-11-07 | $5.12B 10-K · filed 2018-02-16 | $5.14B 10-K · filed 2016-02-19 | |||
| 2015-09-30 | $1.23B 10-Q · filed 2016-11-07 | $1.24B 10-Q · filed 2015-11-06 | $2.60B derived: sum of 2 quarters · filed 2016-11-07 | $3.61B 10-Q · filed 2016-11-07 | $3.63B 10-Q · filed 2015-11-06 | $2.81B derived: sum of 4 quarters · filed 2016-11-07 | ||
| 2015-06-30 | $1.37B 10-Q · filed 2016-08-05 | $2.39B 10-Q · filed 2016-08-05 | $1.58B derived: sum of 3 quarters · filed 2016-08-05 | $2.08B derived: sum of 4 quarters · filed 2016-08-05 | ||||
| 2015-03-31 | $1.02B 10-Q · filed 2016-05-06 | $212.00M derived: sum of 2 quarters · filed 2016-05-06 | $718.00M derived: sum of 3 quarters · filed 2016-05-06 | $1.82B derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2014-12-31 | -$810.00M 10-K · filed 2016-02-19 | -$304.00M derived: sum of 2 quarters · filed 2016-02-19 | $794.00M derived: sum of 3 quarters · filed 2016-02-19 | $1.76B 10-K · filed 2017-02-17 | $1.77B 10-K · filed 2015-02-20 | |||
| 2014-09-30 | $506.00M 10-K · filed 2016-02-19 | $1.60B derived: sum of 2 quarters · filed 2016-02-19 | $2.58B 10-Q · filed 2015-11-06 | $3.71B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $1.10B 10-K · filed 2016-02-19 | $2.08B 10-Q · filed 2015-08-07 | $3.21B derived: sum of 3 quarters · filed 2016-02-19 | $4.17B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | $980.00M 10-K · filed 2016-02-19 | $2.11B derived: sum of 2 quarters · filed 2016-02-19 | $3.07B derived: sum of 3 quarters · filed 2016-02-19 | $4.14B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | $1.13B 10-K · filed 2015-02-20 | $2.09B derived: sum of 2 quarters · filed 2015-02-20 | $3.16B derived: sum of 3 quarters · filed 2015-02-20 | $4.13B 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | $964.00M 10-K · filed 2015-02-20 | $2.03B derived: sum of 2 quarters · filed 2015-02-20 | $3.00B 10-Q · filed 2014-11-07 | $4.54B derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-06-30 | $1.07B 10-K · filed 2015-02-20 | $2.04B 10-Q · filed 2014-08-07 | $3.58B derived: sum of 3 quarters · filed 2015-02-20 | $5.16B derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-03-31 | $968.00M 10-K · filed 2015-02-20 | $2.51B derived: sum of 2 quarters · filed 2015-02-20 | $4.09B derived: sum of 3 quarters · filed 2015-02-20 | $5.36B derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2012-12-31 | $1.54B 10-K · filed 2014-02-21 | $3.13B derived: sum of 2 quarters · filed 2014-02-21 | $4.39B derived: sum of 3 quarters · filed 2014-02-21 | $5.28B 10-K · filed 2015-02-20 | ||||
| 2012-09-30 | $1.58B 10-K · filed 2014-02-21 | $2.85B derived: sum of 2 quarters · filed 2014-02-21 | $3.73B 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | $1.27B 10-K · filed 2014-02-21 | $2.15B 10-Q · filed 2013-08-09 | ||||||
| 2012-03-31 | $883.00M 10-K · filed 2014-02-21 | |||||||
| 2011-12-31 | $3.43B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |